A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
Public ClinicalTrials.gov record NCT03653507. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Study identification
- NCT ID
- NCT03653507
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Enrollment
- 507 participants
Conditions and interventions
Conditions
Interventions
- capecitabine Drug
- oxaliplatin Drug
- placebo Drug
- zolbetuximab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 27, 2018
- Primary completion
- Oct 24, 2022
- Completion
- Sep 29, 2026
- Last update posted
- Apr 16, 2026
2018 – 2026
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pacific Cancer Care | Monterey | California | 93940 | — |
| University of Kansas Cancer Center and Medical Pavilion | Fairway | Kansas | 66205 | — |
| Ochsner Clinic CCOP | New Orleans | Louisiana | 70121 | — |
| New Mexico Oncology Hematology | Albuquerque | New Mexico | 87109 | — |
| Weill Cornell Medical College (WCMC) | New York | New York | 10021 | — |
| Montefiore Medical Center (MMC) | The Bronx | New York | 10467 | — |
| Prisma Health Cancer Institute | Boiling Springs | South Carolina | 29316 | — |
| Parkland Hospital | Dallas | Texas | 75390 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Houston Methodist Cancer Center and Institute of Academic Medicine - Oncology | Houston | Texas | 77030 | — |
| Utah Cancer Specialist | Salt Lake City | Utah | 84106 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 154 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03653507, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03653507 live on ClinicalTrials.gov.